Serum tri‐ and tetra‐antennary <i>N</i>‐glycan is a potential predictive biomarker for castration‐resistant prostate cancer

Ishibashi, Yutaka; Tobisawa, Yuki; Hatakeyama, Shingo; Ohashi, Tetsu; Tanaka, Masakazu; Narita, Shintaro; Koie, Takuya; Habuchi, Tomonori; Nishimura, Shin‐Ichiro; Οhyama, Chikara; Yoneyama, T.

doi:10.1002/pros.22869

Cited by 52 publications

(67 citation statements)

References 28 publications

(37 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies have shown that differences in serum N-glycan profiles between diseased and benign states analyzing high-throughput, comprehensive and quantitative N-glycomics may be useful in the diagnosis or prognosis of diseases [11][12][13][14]19]. A few studies have investigated the use of serum N-glycans as diagnostic markers for UC, including UTUC [13,19].…”

Section: Discussionmentioning

confidence: 99%

“…A 10-µL aliquot of the purified Igs fractions were analyzed using the glycoblotting method [11,12,15,33] on a Sweetblot instrument (System Instruments, Hachioji, Tokyo, Japan). Then, the resulting benzyloxiamine (BOA)-labelled glycans were detected by matrix-assisted laser desorption time-of-flight (MALDI-TOF) mass spectrometry (Ultraflex 3 TOF/TOF mass spectrometer; Bruker Daltonics, Bremen, Germany) ( Figure A1a-f).…”

Section: Serum N-glycomics Of Igs Performed By Using the Glycoblottinmentioning

confidence: 99%

See 1 more Smart Citation

Aberrant N-glycosylation profile of serum immunoglobulins is a diagnostic biomarker of urothelial carcinomas

Tanaka¹,

Yoneyama²,

Noro³

et al. 2018

European Urology Supplements

View full text Add to dashboard Cite

Abstract:The aim of this study to determine whether the aberrant N-glycosylated serum immunoglobulins (Igs) can be applied as a diagnostic marker of urothelial carcinoma (UC). Between 2009 and 2016, we randomly obtained serum available from 237 UC and also 96 prostate cancer as other cancer controls from our serum bank and also obtained-from 339 healthy volunteers (HV)-controls obtained from community-dwelling volunteers in Iwaki Health Promotion Project. A total of 32 types of N-glycan levels on Igs were determined by high-throughput N-glycomics and analyzed by multivariable discriminant analysis. We found five UC-associated aberrant N-glycans changes on Igs and also found that asialo-bisecting GlcNAc type N-glycan on Igs were significantly accumulated in UC patients. The diagnostic N-glycan Score (dNGScore) established by combination of five N-glycans on Igs discriminated UC patients from HV and prostate cancer (PC) patients with 92.8% sensitivity and 97.2% specificity. The area under the curve (AUC) for of the dNGScore was 0.969 for UC detection that was much superior to that of urine cytology (AUC, 0.707) and hematuria (AUC, 0.892). Furthermore, dNGScore can detect hematuria and urine cytology negative patients. The dNGscore based on aberrant N-glycosylation signatures of Igs were found to be promising diagnostic biomarkers of UCs.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Serum N-glycomics Of Igs Performed By Using the Glycoblottinmentioning

confidence: 99%

Aberrant N-glycosylation profile of serum immunoglobulins is a diagnostic biomarker of urothelial carcinomas

Tanaka¹,

Yoneyama²,

Noro³

et al. 2018

European Urology Supplements

View full text Add to dashboard Cite

show abstract

“…A 10-µL aliquot of whole serum or a Igs fraction purified from whole serum was processed by using the glycoblotting method [8][9][10][11][12][13][14]21] and a controlled automated SweetblotTM instrument (System Instruments, Hachioji, Japan). Then, the resulting BOA-labeled glycans were detected by MALDI-TOF MS (Ultraflex 3 TOF/TOF mass spectrometer; Bruker Daltonics, Bremen, Germany) (Figure 8).…”

Section: Glycoblotting Methods and Mass Spectrometrymentioning

confidence: 99%

Serum aberrant N-glycan profile as a marker associated with early antibody-mediated rejection in patients receiving a living donor kidney transplant

Noro¹,

Yoneyama²,

Hatakeyama³

et al. 2018

European Urology Supplements

View full text Add to dashboard Cite

“…N-glycan structures frequently change in cancer and are linked to disease progression and metastasis (Taniguchi & Kizuka 2015). Increased levels of branched and cryptic N-glycans are common in prostate cancer, have been linked to EMT and metastasis and are currently being investigated as potential diagnostic markers (Kyselova et al 2007, Newsom-Davis et al 2009, Pinho et al 2012, Wang et al 2013, Ishibashi et al 2014, Li et al 2014a, Taniguchi & Kizuka 2015. The expression of six enzymes with roles in N-glycan processing (EDEM3, ST6GAL1, B4GALT1, UGGT1, ALG2 and NEU1) is controlled by the AR in prostate cancer cells .…”

Section: N-glycan Biosynthesis (Ost Complex N-glycan Processing)mentioning

confidence: 99%

Glycosylation is a global target for androgen control in prostate cancer cells

Munkley¹

2017

Endocrine-Related Cancer

View full text Add to dashboard Cite

Changes in glycan composition are common in cancer and can play important roles in all of the recognised hallmarks of cancer. We recently identified glycosylation as a global target for androgen control in prostate cancer cells and further defined a set of 8 glycosylation enzymes (GALNT7, ST6GalNAc1, GCNT1, UAP1, PGM3, CSGALNACT1, ST6GAL1 and EDEM3), which are also significantly upregulated in prostate cancer tissue. These 8 enzymes are under direct control of the androgen receptor (AR) and are linked to the synthesis of important cancer-associated glycans such as sialyl-Tn (sTn), sialyl LewisX (SLeX), O-GlcNAc and chondroitin sulfate. Glycosylation has a key role in many important biological processes in cancer including cell adhesion, migration, interactions with the cell matrix, immune surveillance, cell signalling and cellular metabolism. Our results suggest that alterations in patterns of glycosylation via androgen control might modify some or all of these processes in prostate cancer. The prostate is an abundant secretor of glycoproteins of all types, and alterations in glycans are, therefore, attractive as potential biomarkers and therapeutic targets. Emerging data on these often overlooked glycan modifications have the potential to improve risk stratification and therapeutic strategies in patients with prostate cancer.

show abstract

Serum tri‐ and tetra‐antennary N‐glycan is a potential predictive biomarker for castration‐resistant prostate cancer

Abstract: These results suggest that the overexpression of tri- and tetra-antennary N-glycan may be associated with the castration-resistant status in PC and may be a potential predictive biomarker for CRPC.

Cited by 52 publications

References 28 publications

Aberrant N-glycosylation profile of serum immunoglobulins is a diagnostic biomarker of urothelial carcinomas

Aberrant N-glycosylation profile of serum immunoglobulins is a diagnostic biomarker of urothelial carcinomas

Serum aberrant N-glycan profile as a marker associated with early antibody-mediated rejection in patients receiving a living donor kidney transplant

Glycosylation is a global target for androgen control in prostate cancer cells

Contact Info

Product

Resources

About